ETF Holdings Breakdown of FULC
| Stock Name | Fulcrum Therapeutics Inc |
| Ticker | FULC(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US3596161097 |
FULC institutional holdings
The adjusted close for FULC on 2025-12-24 was 12.01
The following institutional investment holdings of FULC have been identified
Book value of shares is calculated on the adjusted close price of each day (row).News associated with FULC
- Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $7.57
- Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) have been given an average recommendation of “Moderate Buy” by the eight research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, four have issued a buy rating […] - 2025-08-25 03:00:58
- Fulcrum Therapeutics (NASDAQ:FULC) Raised to Buy at HC Wainwright
- HC Wainwright upgraded shares of Fulcrum Therapeutics (NASDAQ:FULC – Free Report) from a neutral rating to a buy rating in a research report released on Tuesday morning, Marketbeat reports. HC Wainwright currently has $12.00 price objective on the stock, up from their previous price objective of $4.00. Other analysts have also recently issued research reports […] - 2025-08-01 02:54:48
- Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $6.29 Consensus Target Price from Analysts
- Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) has been given an average rating of “Moderate Buy” by the eight analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has […] - 2025-07-31 02:36:48
- Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by D. E. Shaw & Co. Inc.
- D. E. Shaw & Co. Inc. reduced its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) by 23.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 583,203 shares of the company’s stock after selling 174,528 shares during the […] - 2025-05-20 05:16:54
- MetLife Investment Management LLC Increases Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)
- MetLife Investment Management LLC increased its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) by 145.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,107 shares of the company’s stock after acquiring an additional 23,792 shares during […] - 2025-05-09 06:32:46
- Hsbc Holdings PLC Raises Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)
- Hsbc Holdings PLC increased its position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) by 55.0% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 75,959 shares of the company’s stock after purchasing an additional 26,944 shares during the period. Hsbc Holdings PLC’s holdings in Fulcrum Therapeutics were worth $355,000 at the end […] - 2025-05-09 05:32:47
- Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $8.63 Consensus Price Target from Analysts
- Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) has earned a consensus recommendation of “Hold” from the nine research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the […] - 2025-04-24 03:05:10
- Wellington Management Group LLP Decreases Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)
- Wellington Management Group LLP reduced its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) by 2.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 172,158 shares of the company’s stock after selling 4,003 shares during the period. Wellington Management Group LLP’s holdings in Fulcrum Therapeutics were worth $809,000 at the end […] - 2025-04-14 04:50:48
- Intech Investment Management LLC Buys 13,057 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)
- Intech Investment Management LLC increased its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) by 74.9% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 30,499 shares of the company’s stock after acquiring an additional 13,057 shares during the period. Intech Investment Management LLC’s holdings in Fulcrum Therapeutics were worth $143,000 at […] - 2025-03-28 06:30:47
- Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $9.33 Average Target Price from Analysts
- Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) has received an average recommendation of “Hold” from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and two have given a buy recommendation to the […] - 2025-03-03 04:32:49
- HC Wainwright Reiterates Neutral Rating for Fulcrum Therapeutics (NASDAQ:FULC)
- Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report)‘s stock had its “neutral” rating reissued by analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $4.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 18.69% from the stock’s current price. HC Wainwright also […] - 2025-02-28 07:16:56
- Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $9.33
- Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) has been assigned a consensus rating of “Hold” from the ten research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company. […] - 2025-02-06 04:24:49
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.
Copyright Market Footprint Ltd. Privacy Policy
1.8%